{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:46:16Z","timestamp":1788997576765,"version":"build-2803163510"},"reference-count":144,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Diabetic kidney disease (DKD) is a major cause of end-stage kidney disease (ESKD) worldwide. Mineralocorticoid receptor (MR) plays an important role in the development of DKD. A series of preclinical studies revealed that MR is overactivated under diabetic conditions, resulting in promoting inflammatory and fibrotic process in the kidney. Clinical studies demonstrated the usefulness of MR antagonists (MRAs), such as spironolactone and eplerenone, on DKD. However, concerns regarding their selectivity for MR and hyperkalemia have remained for these steroidal MRAs. Recently, nonsteroidal MRAs, including finerenone, have been developed. These agents are highly selective and have potent anti-inflammatory and anti-fibrotic properties with a low risk of hyperkalemia. We herein review the current knowledge and future perspectives of MRAs in DKD treatment.<\/jats:p>","DOI":"10.3389\/fphar.2021.754239","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T06:59:38Z","timestamp":1635404378000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":40,"title":["Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease"],"prefix":"10.3389","volume":"12","author":[{"given":"Daiji","family":"Kawanami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Takashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimi","family":"Muta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makito","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and Non-steroidal Mineralocorticoid Receptor Antagonists in Cardiorenal Medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur. Heart J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/dom.13983","article-title":"Non-steroidal Mineralocorticoid Antagonists: Prospects for Renoprotection in Diabetic Kidney Disease","volume":"22","author":"Al Dhaybi","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"B3","doi-asserted-by":"publisher","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","article-title":"Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1","volume":"290","author":"Amazit","year":"2015","journal-title":"J. Biol. Chem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/s41440-020-0495-0","article-title":"Synergistic Reduction in Albuminuria in Type 2 Diabetic Mice by Esaxerenone (CS-3150), a Novel Nonsteroidal Selective Mineralocorticoid Receptor Blocker, Combined with an Angiotensin II Receptor Blocker","volume":"43","author":"Arai","year":"2020","journal-title":"Hypertens. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1126\/science.3037703","article-title":"Cloning of Human Mineralocorticoid Receptor Complementary DNA: Structural and Functional Kinship with the Glucocorticoid Receptor","volume":"237","author":"Arriza","year":"1987","journal-title":"Science"},{"key":"B6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00424-012-1120-0","article-title":"ACE2, Angiotensin-(1\u20137), and Mas: the Other Side of the coin","volume":"465","author":"Bader","year":"2013","journal-title":"Pflugers Arch."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1900\/RDS.2021.17.1","article-title":"Molecular Mechanisms Involved in Intrarenal Renin-Angiotensin and Alternative Pathways in Diabetic Nephropathy - A Review","volume":"17","author":"Bahreini","year":"2021","journal-title":"Rev. Diabet Stud."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of Finerenone on Albuminuria in Patients with Diabetic NephropathyEffect of Finerenone on Albuminuria in Patients with Diabetic Nephropathy: A Randomized Clinical Trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1681\/ASN.2016040477","article-title":"Benefit of Mineralocorticoid Receptor Antagonism in AKI: Role of Vascular Smooth Muscle Rac1","volume":"28","author":"Barrera-Chimal","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","article-title":"The Myeloid Mineralocorticoid Receptor Controls Inflammatory and Fibrotic Responses after Renal Injury via Macrophage Interleukin-4 Receptor Signaling","volume":"93","author":"Barrera-Chimal","year":"2018","journal-title":"Kidney Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1159\/000480652","article-title":"The Role of the Mineralocorticoid Receptor in Inflammation: Focus on Kidney and Vasculature","volume":"46","author":"Belden","year":"2017","journal-title":"Am. J. Nephrol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"9424","DOI":"10.1073\/pnas.95.16.9424","article-title":"Mineralocorticoid Receptor Knockout Mice: Pathophysiology of Na+ Metabolism","volume":"95","author":"Berger","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B14","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/s41440-019-0211-0","article-title":"Effect of a Novel Nonsteroidal Selective Mineralocorticoid Receptor Antagonist, Esaxerenone (CS-3150), on Blood Pressure and Renal Injury in High Salt-Treated Type 2 Diabetic Mice","volume":"42","author":"Bhuiyan","year":"2019","journal-title":"Hypertens. Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/ki.2013.175","article-title":"Divergent Functions of the Rho GTPases Rac1 and Cdc42 in Podocyte Injury","volume":"84","author":"Blattner","year":"2013","journal-title":"Kidney Int."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007004.pub3","article-title":"Aldosterone Antagonists for Preventing the Progression of Chronic Kidney Disease","author":"Bolignano","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"F891","DOI":"10.1152\/ajprenal.1993.264.5.F891","article-title":"Proximal Tubular Secretion of Angiotensin II in Rats","volume":"264","author":"Braam","year":"1993","journal-title":"Am. J. Physiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1042\/CS20140432","article-title":"Therapeutic Targeting of Aldosterone: a Novel Approach to the Treatment of Glomerular Disease","volume":"128","author":"Brem","year":"2015","journal-title":"Clin. Sci. (Lond)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1007\/s00125-016-4021-5","article-title":"JAK Inhibition in the Treatment of Diabetic Kidney Disease","volume":"59","author":"Brosius","year":"2016","journal-title":"Diabetologia"},{"key":"B20","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/j.1365-2265.2011.04148.x","article-title":"Mineralocorticoid Antagonism: a Novel Way to Treat Sarcopenia and Physical Impairment in Older People?","volume":"75","author":"Burton","year":"2011","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"111115","DOI":"10.1016\/j.mce.2020.111115","article-title":"Non-coding RNAs and the Mineralocorticoid Receptor in the Kidney","volume":"521","author":"Butterworth","year":"2021","journal-title":"Mol. Cel Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"F405","DOI":"10.1152\/ajprenal.1997.272.3.F405","article-title":"Angiotensin I-Converting Enzyme Activity in Tubular Fluid along the Rat Nephron","volume":"272","author":"Casarini","year":"1997","journal-title":"Am. J. Physiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.gene.2013.08.047","article-title":"Aldosterone Stimulates Fibronectin Synthesis in Renal Fibroblasts through Mineralocorticoid Receptor-dependent and Independent Mechanisms","volume":"531","author":"Chen","year":"2013","journal-title":"Gene"},{"key":"B24","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ki.2010.214","article-title":"Serum- and Glucocorticoid-Regulated Kinase 1 Is Upregulated Following Unilateral Ureteral Obstruction Causing Epithelial-Mesenchymal Transition","volume":"78","author":"Cheng","year":"2010","journal-title":"Kidney Int."},{"key":"B25","doi-asserted-by":"publisher","first-page":"T83","DOI":"10.1530\/JOE-17-0155","article-title":"30 YEARS of the MINERALOCORTICOID RECEPTOR: Mineralocorticoid Receptor Null Mice: Informing Cell-type-specific Roles","volume":"234","author":"Cole","year":"2017","journal-title":"J. Endocrinol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1124\/dmd.31.11.1448","article-title":"Pharmacokinetics and Metabolism of [14C]eplerenone after Oral Administration to Humans","volume":"31","author":"Cook","year":"2003","journal-title":"Drug Metab. Dispos"},{"key":"B27","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s11906-017-0778-2","article-title":"Intrarenal Angiotensin-Converting Enzyme: the Old and the New","volume":"19","author":"Culver","year":"2017","journal-title":"Curr. Hypertens. Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12882-016-0337-0","article-title":"Effect of Mineralocorticoid Receptor Antagonists on Proteinuria and Progression of Chronic Kidney Disease: a Systematic Review and Meta-Analysis","volume":"17","author":"Currie","year":"2016","journal-title":"BMC Nephrol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1161\/HYPERTENSIONAHA.117.09598","article-title":"Endothelial Mineralocorticoid Receptor Mediates Parenchymal Arteriole and Posterior Cerebral Artery Remodeling during Angiotensin II-Induced Hypertension","volume":"70","author":"Diaz-Otero","year":"2017","journal-title":"Hypertension"},{"key":"B30","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s11255-019-02074-9","article-title":"Spironolactone Alleviates Diabetic Nephropathy through Promoting Autophagy in Podocytes","volume":"51","author":"Dong","year":"2019","journal-title":"Int. Urol. Nephrol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1161\/01.res.85.7.643","article-title":"The Cardiac Renin-Angiotensin System: Conceptual, or a Regulator of Cardiac Function?","volume":"85","author":"Dostal","year":"1999","journal-title":"Circ. Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1159\/000508670","article-title":"A Prospective Single-Blind Randomized Trial of Ramipril, Eplerenone and Their Combination in Type 2 Diabetic Nephropathy","volume":"10","author":"El Mokadem","year":"2020","journal-title":"Cardiorenal Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.kisu.2016.01.004","article-title":"Hyperkalemia Constitutes a Constraint for Implementing Renin-Angiotensin-Aldosterone Inhibition: the Widening gap between Mandated Treatment Guidelines and the Real-World Clinical arena","volume":"6","author":"Epstein","year":"20162011","journal-title":"Kidney Int. Suppl. (2011)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 Diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1042\/bst0130042","article-title":"Structure and Functions of Human Angiotensin I Converting Enzyme (Kininase II)","volume":"13","author":"Erd\u00f6s","year":"1985","journal-title":"Biochem. Soc. Trans."},{"key":"B36","doi-asserted-by":"publisher","first-page":"F322","DOI":"10.1152\/ajprenal.00260.2015","article-title":"Assessment of Urinary Angiotensinogen as a Marker of Podocyte Injury in Proteinuric Nephropathies","volume":"310","author":"Eriguchi","year":"2016","journal-title":"Am. J. Physiol. Ren. Physiol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1093\/ndt\/gft281","article-title":"Long-term Effects of Addition of Mineralocorticoid Receptor Antagonist to Angiotensin II Receptor Blocker in Patients with Diabetic Nephropathy: a Randomized Clinical Trial","volume":"28","author":"Esteghamati","year":"2013","journal-title":"Nephrol. Dial. Transpl."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A Randomized Controlled Study of Finerenone vs. Eplerenone in Patients with Worsening Chronic Heart Failure and Diabetes Mellitus And\/or Chronic Kidney Disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur. Heart J."},{"key":"B39","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jacc.2021.04.079","article-title":"Finerenone Reduces New-Onset Atrial Fibrillation in Patients with Chronic Kidney Disease and Type 2 Diabetes","volume":"78","author":"Filippatos","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1152\/physrev.00038.2017","article-title":"Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology","volume":"98","author":"Forrester","year":"2018","journal-title":"Physiol. Rev."},{"key":"B41","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/MNH.0000000000000557","article-title":"Mitigating Risk of Aldosterone in Diabetic Kidney Disease","volume":"29","author":"Frimodt-M\u00f8ller","year":"2020","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1111\/j.1523-1755.2004.00913.x","article-title":"Spironolactone Prevents Early Renal Injury in Streptozotocin-Induced Diabetic Rats","volume":"66","author":"Fujisawa","year":"2004","journal-title":"Kidney Int."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.vh.2018.09.001","article-title":"Aldosterone Research: 65 years, and Counting","volume":"109","author":"Funder","year":"2019","journal-title":"Vitam Horm."},{"key":"B44","doi-asserted-by":"publisher","first-page":"5098","DOI":"10.1210\/en.2010-0465","article-title":"Minireview: Aldosterone and Mineralocorticoid Receptors: Past, Present, and Future","volume":"151","author":"Funder","year":"2010","journal-title":"Endocrinology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/j.1552-4604.1989.tb03339.x","article-title":"Spironolactone Metabolism: Steady-State Serum Levels of the Sulfur-Containing Metabolites","volume":"29","author":"Gardiner","year":"1989","journal-title":"J. Clin. Pharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"78","DOI":"10.2174\/1574884713666181116100946","article-title":"The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy","volume":"14","author":"Goenka","year":"2019","journal-title":"Curr. Clin. Pharmacol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/cphy.c130044","article-title":"The Multifaceted Mineralocorticoid Receptor","volume":"4","author":"Gomez-Sanchez","year":"2014","journal-title":"Compr. Physiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"F772","DOI":"10.1152\/ajprenal.00019.2008","article-title":"Intrarenal Angiotensin II and Angiotensinogen Augmentation in Chronic Angiotensin II-Infused Mice","volume":"295","author":"Gonzalez-Villalobos","year":"2008","journal-title":"Am. J. Physiol. Ren. Physiol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1161\/01.HYP.0000259797.48382.b2","article-title":"Nongenomic Actions of Aldosterone on the Renal Tubule","volume":"49","author":"Good","year":"2007","journal-title":"Hypertension"},{"key":"B50","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/FJC.0000000000000366","article-title":"Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-Induced Cardiac Hypertrophy","volume":"67","author":"Grune","year":"2016","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"key":"B52","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.mce.2011.07.034","article-title":"Acute and Chronic Regulation of Aldosterone Production","volume":"350","author":"Hattangady","year":"2012","journal-title":"Mol. Cel Endocrinol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1161\/HYPERTENSIONAHA.121.17263","article-title":"Activation of Rac1-Mineralocorticoid Receptor Pathway Contributes to Renal Injury in Salt-Loaded Db\/db Mice","volume":"78","author":"Hirohama","year":"2021","journal-title":"Hypertension"},{"key":"B54","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ejphar.2014.10.021","article-title":"Combination Therapy with Spironolactone and Candesartan Protects against Streptozotocin-Induced Diabetic Nephropathy in Rats","volume":"744","author":"Hofni","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1016\/j.clinthera.2015.05.508","article-title":"Spironolactone Add-On for Preventing or Slowing the Progression of Diabetic Nephropathy: A Meta-Analysis","volume":"37","author":"Hou","year":"2015","journal-title":"Clin. Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1159\/000339500","article-title":"Aldosterone Induces Kidney Fibroblast Proliferation via Activation of Growth Factor Receptors and PI3K\/MAPK Signalling","volume":"120","author":"Huang","year":"2012","journal-title":"Nephron Exp. Nephrol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients with Essential Hypertension (ESAX-HTN Study)","volume":"75","author":"Ito","year":"","journal-title":"Hypertension"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial","volume":"15","author":"Ito","year":"","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2215\/CJN.14751218","article-title":"Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial","volume":"14","author":"Ito","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-021-02075-y","article-title":"Efficacy and Safety of Esaxerenone (CS-3150) in Japanese Patients with Type 2 Diabetes and Macroalbuminuria: a Multicenter, Single-Arm, Open-Label Phase III Study","author":"Ito","year":"2021","journal-title":"Clin. Exp. Nephrol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"530","DOI":"10.7150\/ijbs.8450","article-title":"Detailed Localization of Augmented Angiotensinogen mRNA and Protein in Proximal Tubule Segments of Diabetic Kidneys in Rats and Humans","volume":"10","author":"Kamiyama","year":"2014","journal-title":"Int. J. Biol. Sci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.phrs.2017.07.008","article-title":"AT2 Receptors in Cardiovascular and Renal Diseases","volume":"125","author":"Kaschina","year":"2017","journal-title":"Pharmacol. Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1007\/s10157-015-1106-2","article-title":"Anti-albuminuric Effects of Spironolactone in Patients with Type 2 Diabetic Nephropathy: a Multicenter, Randomized Clinical Trial","volume":"19","author":"Kato","year":"2015","journal-title":"Clin. Exp. Nephrol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"E425","DOI":"10.1152\/ajpendo.00227.2011","article-title":"NADPH Oxidase-Mediated Rac1 GTP Activity Is Necessary for Nongenomic Actions of the Mineralocorticoid Receptor in the CA1 Region of the Rat hippocampus","volume":"302","author":"Kawakami-Mori","year":"2012","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1161\/01.hyp.37.5.1329","article-title":"Enhancement of Angiotensinogen Expression in Angiotensin II-dependent Hypertension","volume":"37","author":"Kobori","year":"2001","journal-title":"Hypertension"},{"key":"B66","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1161\/01.hyp.0000050102.90932.cf","article-title":"Urinary Angiotensinogen as an Indicator of Intrarenal Angiotensin Status in Hypertension","volume":"41","author":"Kobori","year":"2003","journal-title":"Hypertension"},{"key":"B67","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects from Rat Cardiorenal Injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000516213","article-title":"Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage","author":"Kolkhof","year":"2021","journal-title":"Am. J. Nephrol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1161\/01.HYP.0000081221.36703.01","article-title":"Angiotensin I Conversion to Angiotensin II Stimulates Cortical Collecting Duct Sodium Transport","volume":"42","author":"Komlosi","year":"2003","journal-title":"Hypertension"},{"key":"B70","first-page":"1900","article-title":"Production of Aldosterone by Rat Mesangial Cell and the Accumulation of Extracellular Matrix Induced by Aldosterone","volume":"83","author":"Lai","year":"2003","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1161\/01.hyp.0000016177.20565.a0","article-title":"Effects of Dietary Sodium and Genetic Background on Angiotensinogen and Renin in Mouse","volume":"39","author":"Lantelme","year":"2002","journal-title":"Hypertension"},{"key":"B72","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1161\/HYPERTENSIONAHA.116.08526","article-title":"Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects against Acute Kidney Injury-Mediated Chronic Kidney Disease: Role of Oxidative Stress","volume":"69","author":"Lattenist","year":"2017","journal-title":"Hypertension"},{"key":"B73","doi-asserted-by":"publisher","first-page":"6656","DOI":"10.1074\/jbc.M113.519256","article-title":"The Mineralocorticoid Receptor Promotes Fibrotic Remodeling in Atrial Fibrillation","volume":"289","author":"Lavall","year":"2014","journal-title":"J. Biol. Chem."},{"key":"B74","doi-asserted-by":"publisher","first-page":"e21314","DOI":"10.1096\/fj.202002043RR","article-title":"Antagonistic Effects of Finerenone and Spironolactone on the Aldosterone-Regulated Transcriptome of Human Kidney Cells","volume":"35","author":"Le Billan","year":"2021","journal-title":"FASEB J."},{"key":"B75","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3803\/EnM.2021.1108","article-title":"Aldosterone Inhibits In Vitro Myogenesis by Increasing Intracellular Oxidative Stress via Mineralocorticoid Receptor","volume":"36","author":"Lee","year":"2021","journal-title":"Endocrinol. Metab. (Seoul)"},{"key":"B76","doi-asserted-by":"publisher","first-page":"130","DOI":"10.4093\/dmj.2011.35.2.130","article-title":"Effects of Spironolactone and Losartan on Diabetic Nephropathy in a Type 2 Diabetic Rat Model","volume":"35","author":"Lee","year":"2011","journal-title":"Diabetes Metab. J."},{"key":"B77","doi-asserted-by":"publisher","first-page":"F1381","DOI":"10.1152\/ajprenal.00101.2009","article-title":"Activation of Local Aldosterone System within Podocytes Is Involved in Apoptosis under Diabetic Conditions","volume":"297","author":"Lee","year":"2009","journal-title":"Am. J. Physiol. Ren. Physiol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/path.1670","article-title":"Renal ACE2 Expression in Human Kidney Disease","volume":"204","author":"Lely","year":"2004","journal-title":"J. Pathol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/fcp.12170","article-title":"Pharmacokinetics, Safety and Tolerability of the Novel, Selective Mineralocorticoid Receptor Antagonist Finerenone - Results from First-In-Man and Relative Bioavailability Studies","volume":"30","author":"Lentini","year":"2016","journal-title":"Fundam. Clin. Pharmacol."},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20160086","article-title":"Spironolactone Promotes Autophagy via Inhibiting PI3K\/AKT\/mTOR Signalling Pathway and Reduce Adhesive Capacity Damage in Podocytes under Mechanical Stress","volume":"36","author":"Li","year":"2016","journal-title":"Biosci. Rep."},{"key":"B81","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41440-018-0187-1","article-title":"Effects of the Novel Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone (CS-3150), on Blood Pressure and Urinary Angiotensinogen in Low-Renin Dahl Salt-Sensitive Hypertensive Rats","volume":"42","author":"Li","year":"2019","journal-title":"Hypertens. Res."},{"key":"B82","doi-asserted-by":"publisher","first-page":"6849","DOI":"10.3892\/mmr.2015.4295","article-title":"Spironolactone Inhibits Podocyte Motility via Decreasing Integrin \u03b21 and Increasing Integrin \u03b23 in Podocytes under High-Glucose Conditions","volume":"12","author":"Li","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"B83","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1093\/ndt\/gfr495","article-title":"Long-term Mineralocorticoid Receptor Blockade Ameliorates Progression of Experimental Diabetic Renal Disease","volume":"27","author":"Lian","year":"2012","journal-title":"Nephrol. Dial. Transpl."},{"key":"B84","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1177\/1470320310369603","article-title":"Spironolactone Ameliorates Podocytic Adhesive Capacity via Restoring Integrin Alpha 3 Expression in Streptozotocin-Induced Diabetic Rats","volume":"11","author":"Lin","year":"2010","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"B85","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/HJH.0b013e3283346b62","article-title":"Involvement of Mineralocorticoid Receptor in High Glucose-Induced Big Mitogen-Activated Protein Kinase 1 Activation and Mesangial Cell Proliferation","volume":"28","author":"Liu","year":"2010","journal-title":"J. Hypertens."},{"key":"B86","doi-asserted-by":"publisher","first-page":"e12148","DOI":"10.5812\/numonthly.12148","article-title":"Effect of Spironolactone on Diabetic Nephropathy Compared to the Combination of Spironolactone and Losartan","volume":"6","author":"Makhlough","year":"2014","journal-title":"Nephrourol Mon"},{"key":"B87","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"C82","DOI":"10.1152\/ajpcell.00287.2006","article-title":"Angiotensin II Cell Signaling: Physiological and Pathological Effects in the Cardiovascular System","volume":"292","author":"Mehta","year":"2007","journal-title":"Am. J. Physiol. Cel Physiol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"10482","DOI":"10.26355\/eurrev_201912_19687","article-title":"Regulatory Mechanism of TGF-\u03921\/sgk1 Pathway in Tubulointerstitial Fibrosis of Diabetic Nephropathy","volume":"23","author":"Miao","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B90","doi-asserted-by":"publisher","first-page":"e0177362","DOI":"10.1371\/journal.pone.0177362","article-title":"Aldosterone Signaling Regulates the Over-expression of Claudin-4 and -8 at the Distal Nephron from Type 1 Diabetic Rats","volume":"12","author":"Molina-Jij\u00f3n","year":"2017","journal-title":"PLoS One"},{"key":"B91","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1161\/HYPERTENSIONAHA.111.185520","article-title":"Oxidative Stress Causes Mineralocorticoid Receptor Activation in Rat Cardiomyocytes: Role of Small GTPase Rac1","volume":"59","author":"Nagase","year":"2012","journal-title":"Hypertension"},{"key":"B92","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2174\/157339911794273919","article-title":"Endocrinological Aspects of Proteinuria and Podocytopathy in Diabetes: Role of the Aldosterone\/mineralocorticoid Receptor System","volume":"7","author":"Nagase","year":"2011","journal-title":"Curr. Diabetes Rev."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1161\/01.HYP.0000222003.28517.99","article-title":"Podocyte Injury Underlies the Glomerulopathy of Dahl Salt-Hypertensive Rats and Is Reversed by Aldosterone Blocker","volume":"47","author":"Nagase","year":"2006","journal-title":"Hypertension"},{"key":"B94","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1055\/s-0031-1296310","article-title":"Effect of Atorvastatin on Aldosterone Production Induced by Glucose, LDL or Angiotensin II in Human Renal Mesangial Cells","volume":"60","author":"Nishikawa","year":"2010","journal-title":"Arzneimittelforschung"},{"key":"B95","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jsbmb.2005.03.005","article-title":"Human Renal Mesangial Cells Produce Aldosterone in Response to Low-Density Lipoprotein (LDL)","volume":"96","author":"Nishikawa","year":"2005","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s10157-018-1567-1","article-title":"Independent Regulation of Renin-Angiotensin-Aldosterone System in the Kidney","volume":"22","author":"Nishiyama","year":"2018","journal-title":"Clin. Exp. Nephrol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1124\/jpet.109.158113","article-title":"Mineralocorticoid Receptor Blockade Enhances the Antiproteinuric Effect of an Angiotensin II Blocker through Inhibiting Podocyte Injury in Type 2 Diabetic Rats","volume":"332","author":"Nishiyama","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B98","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1097\/01.asn.0000026610.48842.cb","article-title":"Renal Interstitial Fluid Angiotensin I and Angiotensin II Concentrations during Local Angiotensin-Converting Enzyme Inhibition","volume":"13","author":"Nishiyama","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/hr.2010.143","article-title":"Glomerular Angiotensinogen Is Induced in Mesangial Cells in Diabetic Rats via Reactive Oxygen Species--ERK\/JNK Pathways","volume":"33","author":"Ohashi","year":"2010","journal-title":"Hypertens. Res."},{"key":"B100","doi-asserted-by":"crossref","DOI":"10.1111\/hepr.13695","article-title":"Efficacy and Safety of Apararenone (MT-3995) in Patients with Nonalcoholic Steatohepatitis: A Randomized Controlled Study","author":"Okanoue","year":"2021","journal-title":"Hepatol. Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.4172\/2155-6156.1000615","article-title":"Angiotensin-(1-7): A Novel Peptide to Treat Hypertension and Nephropathy in Diabetes?","volume":"6","author":"Padda","year":"2015","journal-title":"J. Diabetes Metab."},{"key":"B102","doi-asserted-by":"publisher","first-page":"m4573","DOI":"10.1136\/bmj.m4573","article-title":"Sodium-glucose Cotransporter Protein-2 (SGLT-2) Inhibitors and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists for Type 2 Diabetes: Systematic Review and Network Meta-Analysis of Randomised Controlled Trials","volume":"372","author":"Palmer","year":"2021","journal-title":"BMJ"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19123764","article-title":"Novel Insights into the Crosstalk between Mineralocorticoid Receptor and G Protein-Coupled Receptors in Heart Adverse Remodeling and Disease","volume":"19","author":"Parker","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"B104","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/cercor\/bhz108","article-title":"Corticosteroids and Regional Variations in Thickness of the Human Cerebral Cortex across the Lifespan","volume":"30","author":"Parker","year":"2020","journal-title":"Cereb. Cortex"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1177\/1470320316652047","article-title":"Prevention of Microalbuminuria Using Early Intervention with Renin-Angiotensin System Inhibitors in Patients with Type 2 Diabetes: A Systematic Review","volume":"17","author":"Persson","year":"2016","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"B106","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and Tolerability of the Novel Non-steroidal Mineralocorticoid Receptor Antagonist BAY 94-8862 in Patients with Chronic Heart Failure and Mild or Moderate Chronic Kidney Disease: a Randomized, Double-Blind Trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur. Heart J."},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/nejmoa030207","article-title":"Eplerenone Post-Acute Myocardial Infarction Heart Failure, E., and Survival Study, IEplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B109","first-page":"1801","article-title":"Studies on Organ- and Subcellular Distribution of 3 H-Spironolactone in Animals","volume":"22","author":"Platt","year":"1972","journal-title":"Arzneimittelforschung"},{"key":"B110","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1093\/eurheartj\/ehr266","article-title":"Aldosterone Promotes Atrial Fibrillation","volume":"33","author":"Reil","year":"2012","journal-title":"Eur. Heart J."},{"key":"B111","doi-asserted-by":"publisher","first-page":"F181","DOI":"10.1152\/ajprenal.1983.245.2.F181","article-title":"Effects on Renal Hemodynamics of Intra-arterial Infusions of Angiotensins I and II","volume":"245","author":"Rosivall","year":"1983","journal-title":"Am. J. Physiol."},{"key":"B112","doi-asserted-by":"crossref","DOI":"10.1111\/dom.14558","article-title":"Efficacy and Safety of Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes by GLP-1RA Treatment: A Subgroup Analysis from the FIDELIO-DKD Trial","author":"Rossing","year":"2021","journal-title":"Diabetes Obes. Metab"},{"key":"B113","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000503712","article-title":"Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial","volume":"50","author":"Ruilope","year":"2019","journal-title":"Am. J. Nephrol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, Mortality, and Kidney Outcomes with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes: a Systematic Review and Meta-Analysis of Randomised Trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1172\/JCI114846","article-title":"Endogenous Angiotensin Concentrations in Specific Intrarenal Fluid Compartments of the Rat","volume":"86","author":"Seikaly","year":"1990","journal-title":"J. Clin. Invest."},{"key":"B116","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1042\/CS20140329","article-title":"Angiotensin-(1-7) Prevents Systemic Hypertension, Attenuates Oxidative Stress and Tubulointerstitial Fibrosis, and Normalizes Renal Angiotensin-Converting Enzyme 2 and Mas Receptor Expression in Diabetic Mice","volume":"128","author":"Shi","year":"2015","journal-title":"Clin. Sci. (Lond)"},{"key":"B117","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1172\/JCI43124","article-title":"Rac1 GTPase in Rodent Kidneys Is Essential for Salt-Sensitive Hypertension via a Mineralocorticoid Receptor-dependent Pathway","volume":"121","author":"Shibata","year":"2011","journal-title":"J. Clin. Invest."},{"key":"B118","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1681\/ASN.2005050571","article-title":"Fluvastatin Ameliorates Podocyte Injury in Proteinuric Rats via Modulation of Excessive Rho Signaling","volume":"17","author":"Shibata","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/nm.1879","article-title":"Modification of Mineralocorticoid Receptor Function by Rac1 GTPase: Implication in Proteinuric Kidney Disease","volume":"14","author":"Shibata","year":"2008","journal-title":"Nat. Med."},{"key":"B120","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.cmet.2013.10.005","article-title":"Mineralocorticoid Receptor Phosphorylation Regulates Ligand Binding and Renal Response to Volume Depletion and Hyperkalemia","volume":"18","author":"Shibata","year":"2013","journal-title":"Cell Metab"},{"key":"B121","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1113\/expphysiol.2008.042085","article-title":"Local Renal Aldosterone Production Induces Inflammation and Matrix Formation in Kidneys of Diabetic Rats","volume":"93","author":"Siragy","year":"2008","journal-title":"Exp. Physiol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"e019437","DOI":"10.1161\/JAHA.120.019437","article-title":"Podocyte Glucocorticoid Receptors Are Essential for Glomerular Endothelial Cell Homeostasis in Diabetes Mellitus","volume":"10","author":"Srivastava","year":"","journal-title":"J. Am. Heart Assoc."},{"key":"B123","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1038\/s41467-021-22617-y","article-title":"Loss of Endothelial Glucocorticoid Receptor Accelerates Diabetic Nephropathy","volume":"12","author":"Srivastava","year":"","journal-title":"Nat. Commun."},{"key":"B124","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ejphar.2008.06.019","article-title":"Spironolactone Exhibits Direct Renoprotective Effects and Inhibits Renal Renin-Angiotensin-Aldosterone System in Diabetic Rats","volume":"589","author":"Taira","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1002\/1873-3468.13746","article-title":"Crystal Structure of the Mineralocorticoid Receptor Ligand-Binding Domain in Complex with a Potent and Selective Nonsteroidal Blocker, Esaxerenone (CS-3150)","volume":"594","author":"Takahashi","year":"2020","journal-title":"FEBS Lett."},{"key":"B126","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S2213-8587(20)30026-7","article-title":"Early Detection of Diabetic Kidney Disease by Urinary Proteomics and Subsequent Intervention with Spironolactone to Delay Progression (PRIORITY): a Prospective Observational Study and Embedded Randomised Placebo-Controlled Trial","volume":"8","author":"Tofte","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1093\/ndt\/gfq750","article-title":"Spironolactone Inhibits Hyperglycemia-Induced Podocyte Injury by Attenuating ROS Production","volume":"26","author":"Toyonaga","year":"2011","journal-title":"Nephrol. Dial. Transpl."},{"key":"B128","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/1470320311412811","article-title":"The Long-Term Antiproteinuric Effect of Eplerenone, a Selective Aldosterone Blocker, in Patients with Non-diabetic Chronic Kidney Disease","volume":"13","author":"Tsuboi","year":"2012","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"B129","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic Kidney Disease: a Report from an ADA Consensus Conference","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s13300-021-01085-z","article-title":"The Role of Finerenone in the Management of Diabetic Nephropathy","volume":"12","author":"Veneti","year":"2021","journal-title":"Diabetes Ther."},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3390\/ph14060561","article-title":"Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease","volume":"14","author":"Vodo\u0161ek Hojs","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"B132","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s10157-020-01963-z","article-title":"Apararenone in Patients with Diabetic Nephropathy: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Dose-Response Study and Open-Label Extension Study","volume":"25","author":"Wada","year":"2021","journal-title":"Clin. Exp. Nephrol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41371-020-0377-6","article-title":"Esaxerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Blocker (MRB) in Hypertension and Chronic Kidney Disease","volume":"35","author":"Wan","year":"2021","journal-title":"J. Hum. Hypertens."},{"key":"B134","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/s0895-7061(02)02957-6","article-title":"Eplerenone, a Selective Aldosterone Blocker, in Mild-To-Moderate Hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am. J. Hypertens."},{"key":"B135","doi-asserted-by":"publisher","first-page":"e014996","DOI":"10.1161\/JAHA.119.014996","article-title":"Effect of Angiotensin II on ENaC in the Distal Convoluted Tubule and in the Cortical Collecting Duct of Mineralocorticoid Receptor Deficient Mice","volume":"9","author":"Wu","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"B136","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/978-1-4939-6625-7_8","article-title":"Measurement of Angiotensin Converting Enzyme 2 Activity in Biological Fluid (ACE2)","volume":"1527","author":"Xiao","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.ahj.2010.04.024","article-title":"Effect of Eplerenone versus Spironolactone on Cortisol and Hemoglobin A\u2081(c) Levels in Patients with Chronic Heart Failure","volume":"160","author":"Yamaji","year":"2010","journal-title":"Am. Heart J."},{"key":"B138","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4093\/dmj.2020.0217","article-title":"Treatment of Diabetic Kidney Disease: Current and Future","volume":"45","author":"Yamazaki","year":"2021","journal-title":"Diabetes Metab. J."},{"key":"B139","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.coph.2016.02.005","article-title":"Mineralocorticoid Receptor Antagonists-Pharmacodynamics and Pharmacokinetic Differences","volume":"27","author":"Yang","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000358758","article-title":"Local Mineralocorticoid Receptor Activation and the Role of Rac1 in Obesity-Related Diabetic Kidney Disease","volume":"126","author":"Yoshida","year":"2014","journal-title":"Nephron Exp. Nephrol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B142","doi-asserted-by":"publisher","first-page":"F723","DOI":"10.1152\/ajprenal.00480.2006","article-title":"Aldosterone Induces Epithelial-Mesenchymal Transition via ROS of Mitochondrial Origin","volume":"293","author":"Zhang","year":"2007","journal-title":"Am. J. Physiol. Ren. Physiol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jash.2016.05.013","article-title":"Spironolactone and Glucose Metabolism, a Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"10","author":"Zhao","year":"2016","journal-title":"J. Am. Soc. Hypertens."},{"key":"B144","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s11010-013-1672-0","article-title":"Spironolactone Inhibits Apoptosis in Rat Mesangial Cells under Hyperglycaemic Conditions via the Wnt Signalling Pathway","volume":"380","author":"Zhu","year":"2013","journal-title":"Mol. Cel Biochem"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.754239\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T10:16:05Z","timestamp":1635761765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.754239\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,28]]},"references-count":144,"alternative-id":["10.3389\/fphar.2021.754239"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.754239","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,28]]},"article-number":"754239"}}